The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia

The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia

The guideline focuses specifically on evidence-based pharmacological and nonpharmacological treatments for schizophrenia and includes statements related to assessment and treatment planning, which are an integral part of patient-centered care. The guideline provides direction on implementing these r...

Full description

Saved in:
Bibliographic Details
Main Author: Association, American Psychiatric
Format: eBook
Language:English
Published: Washington, D.C. : American Psychiatric Association Publishing, 2020.
Edition:3rd ed.
Subjects:
Schizophrenia > Treatment.
Schizophrenia > Treatment
Online Access:Click for online access
Table of Contents:
  • Cover
  • Title
  • Copyright
  • Contents
  • Acronyms/Abbreviations
  • Introduction
  • Rationale
  • Scope of Document
  • Overview of the Development Process
  • Rating the Strengths of Guideline Statements and Supporting Research Evidence
  • Proper Use of Guidelines
  • Guideline Statement Summary
  • Guideline Statements and Implementation
  • Assessment and Determination of Treatment Plan
  • Statement 1: Assessment of Possible Schizophrenia
  • Implementation
  • Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
  • Review of Available Guidelines From Other Organizations
  • Quality Measurement Considerations
  • Statement 2: Use of Quantitative Measures
  • Implementation
  • Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
  • Review of Available Guidelines From Other Organizations
  • Quality Measurement Considerations
  • Statement 3: Evidence-Based Treatment Planning
  • Implementation
  • Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
  • Review of Available Guidelines From Other Organizations
  • Quality Measurement Considerations
  • Pharmacotherapy
  • Statement 4: Antipsychotic Medications
  • Implementation
  • Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
  • Review of Available Guidelines From Other Organizations
  • Quality Measurement Considerations
  • Statement 5: Continuing Medications
  • Implementation
  • Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
  • Review of Available Guidelines From Other Organizations
  • Quality Measurement Considerations
  • Statement 6: Continuing the Same Medications
  • Implementation
  • Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
  • Review of Available Guidelines From Other Organizations
  • Quality Measurement Considerations
  • Statement 7: Clozapine in Treatment-Resistant Schizophrenia
  • Implementation
  • Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
  • Review of Available Guidelines From Other Organizations
  • Quality Measurement Considerations
  • Statement 8: Clozapine in Suicide Risk
  • Implementation
  • Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
  • Review of Available Guidelines From Other Organizations
  • Quality Measurement Considerations
  • Statement 9: Clozapine in Aggressive Behavior
  • Implementation
  • Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
  • Review of Available Guidelines From Other Organizations
  • Quality Measurement Considerations
  • Statement 10: Long-Acting Injectable Antipsychotic Medications
  • Implementation

Similar Items